Kalaris Therapeutics, Inc. (KLRS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 12, 2025, details the results of the 2025 Annual Meeting of Stockholders held by Kalaris Therapeutics, Inc. The Company is incorporated in Delaware and trades on The Nasdaq Global Market under the symbol KLRS. It is designated as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
The primary material event reported is the election of directors and the ratification of the independent auditor. The specific voting outcomes were:
- Director Election (Class II):
- Srinivas Akkaraju, M.D., Ph.D.: 14,626,646 votes For; 144,695 votes Withheld; 1,328,348 Broker Non-Votes.
- Andrew Oxtoby: 14,668,424 votes For; 102,917 votes Withheld; 1,328,348 Broker Non-Votes.
- Auditor Ratification: Stockholders ratified the selection of Deloitte & Touche LLP for the fiscal year ending December 31, 2025.
- Results: 16,090,928 votes For; 6,975 votes Against; 1,786 votes Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural results of the annual meeting.
Key Facts for Investor Verification
- Confirmation of the three-year term for newly elected directors Srinivas Akkaraju and Andrew Oxtoby, expiring at the 2028 annual meeting.
- Verification of the total shares voted and the percentage of broker non-votes (approximately 8.3% of total votes cast for directors).
- Confirmation that Deloitte & Touche LLP remains the independent registered public accounting firm for the 2025 fiscal year.